002412SZSE

2025 Annual Financial Report

✨ AI Summary

This report presents Hunan Hansen Pharmaceutical Co., Ltd.'s 2025 financial results, audited by Zhonghuan Certified Public Accountants. Key figures show total revenue of 103,875.67 million yuan, a 3.41% increase, and net profit attributable to shareholders of 19,812.04 million yuan, a 10.05% decrease. Total assets grew 5.73% to 269,307.39 million yuan, while total liabilities decreased by 9.22% to 312,150.34 million yuan.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_documentSign In to Upgrade

Hunan Hansen Pharmaceutical Co., Ltd. 2025 Annual Financial Report

Hunan Hansen Pharmaceutical Co., Ltd. 2025 financial statements were audited by Zhonghuan Certified Public Accountants (Special General Partnership) and an unqualified audit report was issued on April 24, 2026, with report number Zhonghuan Audit Word (2026) 1100057. The auditor's opinion is that the financial statements are prepared in all material respects in accordance with the Accounting Standards for Business Enterprises, and fairly reflect the consolidated and company's financial position as of December 31, 2025, and the consolidated and company's operating results and cash flows for 2025. The 2025 annual financial report is as follows:

I. Key Financial Indicators Achieved (I) Key Accounting Data

Unit: Ten Thousand Yuan

Item20252024Year-on-Year Change
Total Operating Revenue103,875.67100,446.953.41%
Total Profit23,860.6525,275.66-5.60%
Net Profit Attributable to Shareholders of Listed Company19,812.0422,024.44-10.05%
Net Profit Attributable to Shareholders of Listed Company Excluding Non-recurring Gains and Losses18,987.9121,115.39-10.08%
Net Cash Flow from Operating Activities24,538.1313,078.3887.62%

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.

Notes & Comments

Sign in to leave a comment or private note.

Loading…